Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity.

Arefayene M, Philips S, Cao D, Mamidipalli S, Desta Z, Flockhart DA, Wilkes DS, Skaar TC.

Pharmacogenet Genomics. 2009 Jun;19(6):464-76.

PMID:
19514129
2.

Identification of a variable number of tandem repeats polymorphism and characterization of LEF-1 response elements in the promoter of the IDO1 gene.

Soichot M, Hennart B, Al Saabi A, Leloire A, Froguel P, Levy-Marchal C, Poulain-Godefroy O, Allorge D.

PLoS One. 2011;6(9):e25470. doi: 10.1371/journal.pone.0025470. Epub 2011 Sep 27.

3.

IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism.

Löb S, Königsrainer A, Zieker D, Brücher BL, Rammensee HG, Opelz G, Terness P.

Cancer Immunol Immunother. 2009 Jan;58(1):153-7. doi: 10.1007/s00262-008-0513-6. Epub 2008 Apr 17.

PMID:
18418598
4.

IDO1 and IDO2 non-synonymous gene variants: correlation with crohn's disease risk and clinical phenotype.

Lee A, Kanuri N, Zhang Y, Sayuk GS, Li E, Ciorba MA.

PLoS One. 2014 Dec 26;9(12):e115848. doi: 10.1371/journal.pone.0115848. eCollection 2014. Erratum in: PLoS One. 2015;10(7):e0133098.

5.

Effects of upregulated indoleamine 2, 3-dioxygenase 1 by interferon γ gene transfer on interferon γ-mediated antitumor activity.

Watcharanurak K, Zang L, Nishikawa M, Yoshinaga K, Yamamoto Y, Takahashi Y, Ando M, Saito K, Watanabe Y, Takakura Y.

Gene Ther. 2014 Sep;21(9):794-801. doi: 10.1038/gt.2014.54. Epub 2014 Jun 12.

PMID:
24919418
6.

Is the variant c.422+90G → A in intron 4 of indoleamine 2, 3 -dioxygenase (IDO) gene related to age related cataracts?

Mamata M, Sridhar G, Reddy KR, Nagaraju T, Padma T.

Mol Vis. 2011;17:1203-8. Epub 2011 May 5.

7.

Genetic variation in the indoleamine 2,3-dioxygenase gene in pre-eclampsia.

Nishizawa H, Kato T, Ota S, Nishiyama S, Pryor-Koishi K, Suzuki M, Tsutsumi M, Inagaki H, Kurahashi H, Udagawa Y.

Am J Reprod Immunol. 2010 Jul 1;64(1):68-76. doi: 10.1111/j.1600-0897.2010.00820.x. Epub 2010 Feb 28.

PMID:
20192952
8.

Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells.

Iachininoto MG, Nuzzolo ER, Bonanno G, Mariotti A, Procoli A, Locatelli F, De Cristofaro R, Rutella S.

Molecules. 2013 Aug 22;18(9):10132-45. doi: 10.3390/molecules180910132.

9.

Vascular expression, activity and function of indoleamine 2,3-dioxygenase-1 following cerebral ischaemia-reperfusion in mice.

Jackman KA, Brait VH, Wang Y, Maghzal GJ, Ball HJ, McKenzie G, De Silva TM, Stocker R, Sobey CG.

Naunyn Schmiedebergs Arch Pharmacol. 2011 May;383(5):471-81. doi: 10.1007/s00210-011-0611-4. Epub 2011 Feb 27.

PMID:
21359968
10.

Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.

Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Neilan CL, Haley PJ, Burn TC, Waeltz P, Sparks RB, Yue EW, Combs AP, Scherle PA, Vaddi K, Fridman JS.

Mol Cancer Ther. 2010 Feb;9(2):489-98. doi: 10.1158/1535-7163.MCT-09-0628. Epub 2010 Feb 2.

11.

Comparison of the sequences of Turbo and Sulculus indoleamine dioxygenase-like myoglobin genes.

Suzuki T, Yokouchi K, Kawamichi H, Yamamoto Y, Uda K, Yuasa HJ.

Gene. 2003 Apr 10;308:89-94.

PMID:
12711393
12.

Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies.

Wood TC, Salavagionne OE, Mukherjee B, Wang L, Klumpp AF, Thomae BA, Eckloff BW, Schaid DJ, Wieben ED, Weinshilboum RM.

J Biol Chem. 2006 Mar 17;281(11):7364-73. Epub 2006 Jan 6.

13.

Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells.

Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, Terness P.

Blood. 2008 Feb 15;111(4):2152-4. Epub 2007 Nov 28.

14.

Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues.

Théate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, Hervé C, Gutierrez-Roelens I, Marbaix E, Sempoux C, Van den Eynde BJ.

Cancer Immunol Res. 2015 Feb;3(2):161-72. doi: 10.1158/2326-6066.CIR-14-0137. Epub 2014 Sep 30.

15.

Low efficiency IDO2 enzymes are conserved in lower vertebrates, whereas higher efficiency IDO1 enzymes are dispensable.

Yuasa HJ, Mizuno K, Ball HJ.

FEBS J. 2015 Jul;282(14):2735-45. doi: 10.1111/febs.13316. Epub 2015 May 20.

16.

Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia.

Folgiero V, Goffredo BM, Filippini P, Masetti R, Bonanno G, Caruso R, Bertaina V, Mastronuzzi A, Gaspari S, Zecca M, Torelli GF, Testi AM, Pession A, Locatelli F, Rutella S.

Oncotarget. 2014 Apr 30;5(8):2052-64.

17.

Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration.

Liu XQ, Lu K, Feng LL, Ding M, Gao JM, Ge XL, Wang X.

Leuk Lymphoma. 2014 Feb;55(2):405-14. doi: 10.3109/10428194.2013.804917. Epub 2013 Jun 26.

PMID:
23682557
18.

Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials.

Yuasa HJ, Ball HJ, Ho YF, Austin CJ, Whittington CM, Belov K, Maghzal GJ, Jermiin LS, Hunt NH.

Comp Biochem Physiol B Biochem Mol Biol. 2009 Jun;153(2):137-44.

PMID:
19402226
19.

Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway.

Ball HJ, Yuasa HJ, Austin CJ, Weiser S, Hunt NH.

Int J Biochem Cell Biol. 2009 Mar;41(3):467-71. doi: 10.1016/j.biocel.2008.01.005. Epub 2008 Jan 11. Review.

PMID:
18282734
20.

Human sulfotransferase SULT1C1 pharmacogenetics: gene resequencing and functional genomic studies.

Freimuth RR, Eckloff B, Wieben ED, Weinshilboum RM.

Pharmacogenetics. 2001 Dec;11(9):747-56.

PMID:
11740338

Supplemental Content

Support Center